Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
Value in Health · 2023
DOI: 10.1016/j.jval.2022.12.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2023. Verfasst von Qinglu Cheng und 22 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia. Electronic address: qcheng@kirby.unsw.edu.au. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Substance Abuse, Intravenous, Drug Users, Hepatitis C. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Department of Health and Ageing, Australian Government, Gilead Sciences, AbbVie.
Abstract (Originalsprache)
OBJECTIVES: People who inject drugs (PWID) are at a high risk of hepatitis C virus (HCV) infection. HCV cure is associated with improved patient-reported outcomes (PROs), but there are little data among PWID. This study aimed to assess the change in PROs during and after HCV direct-acting antiviral (DAA) treatment. METHODS: This analysis used data from 2 clinical trials of DAA treatment in PWID. PROs assessed included health-related quality of life, social functioning, psychological distress, housing, and employment. Generalized estimating equations and group-based trajectory modeling were used to assess changes in PROs over time. RESULTS: No significant changes in the 3-level version of EQ-5D scores, EQ visual analogue scale scores, social functioning, psychological distress, and housing were observed over the 108-week study period. There was a significant increase in the proportion of participants employed (18% [95% confidence interval (CI) 12%-23%] at baseline to 28% [95% CI 19%-36%] at the end of the study). Participants were more likely to be employed at 24 weeks and 108 weeks after commencing treatment. Having stable housing increased the odds of being employed (odds ratio 1.70; 95% CI 1.00-2.90). The group-based trajectory modeling demonstrated that most outcomes remained stable during and after DAA treatment. CONCLUSIONS: Although no significant improvement was identified in health-related quality of life after HCV DAA treatment, there was a modest but significant increase in employment during study follow-up. The study findings support the need for multifaceted models of HCV care for PWID addressing a range of issues beyond HCV treatment to improve quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Kirby Institute, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia. Electronic address: qcheng@kirby.unsw.edu.au.
- The Kirby Institute, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.
- The Kirby Institute, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia; Department of Health Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Département de médecine, Université de Montréal, Montréal, QC, Canada.
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England, UK.
- Infection Prevention and Control, Michael Garron Hospital, Toronto, ON, Canada.
Förderung
- Department of Health and Ageing, Australian Government
- Gilead Sciences
- AbbVie
Zitieren
APA
Cheng, Q., Cunningham, E. B., Shih, S., Amin, J., Bruneau, J., Artenie, A. A., Powis, J., Litwin, A. H., Cooper, C., Dalgard, O., Hellard, M., Bruggmann, P., Marks, P., Lacombe, K., Stedman, C., Read, P., Hajarizadeh, B., Dunlop, A. J., Conway, B., …, & SIMPLIFY and D3FEAT Study Groups (2023). Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs. Value in Health. https://doi.org/10.1016/j.jval.2022.12.016
Vancouver
Cheng Q, Cunningham EB, Shih S, Amin J, Bruneau J, Artenie AA, et al. Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs. Value in Health. 2023. doi:10.1016/j.jval.2022.12.016
BibTeX
@article{Cheng2023,
author = {Cheng, Qinglu and Cunningham, Evan B and Shih, Sophy and Amin, Janaki and Bruneau, Julie and Artenie, Adelina A and Powis, Jeff and Litwin, Alain H and Cooper, Curtis and Dalgard, Olav and Hellard, Margaret and Bruggmann, Philip and Marks, Philippa and Lacombe, Karine and Stedman, Catherine and Read, Phillip and Hajarizadeh, Behzad and Dunlop, Adrian J and Conway, Brian and Feld, Jordan J and Dore, Gregory J and Grebely, Jason and SIMPLIFY and D3FEAT Study Groups, SIMPLIFY and D3FEAT Study Groups},
title = {Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs},
journal = {Value in Health},
year = {2023},
doi = {10.1016/j.jval.2022.12.016}
}
EUVIMED